Lisa Ricciardi, president and CEO of Cognition Therapeutics was recently a guest on Benzinga's All-Access. Cognition ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Several recent studies have suggested HRT is a risk factor in various conditions, notably Alzheimer's - now UK boffins have ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...

Nov. 19, 2024 — Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new ... Earlier Diabetes Diagnosis Linked to Dementia Risk Nov. 19, 2024 ...

2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Unhappily, oxybutynin hydrochloride, tolterodine tartrate and solifenacin succinate – the three linked to dementia – are considered the most effective drugs for treating overactive bladder.

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...